Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223. We include data on and a discussion of duration of treatment with zoledronic acid and denosumab, the only two of these agents that do not have a clinically proven anticancer effect. Finally, we review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Original languageEnglish (US)
Pages (from-to)416-423
Number of pages8
JournalOncology (Williston Park, N.Y.)
Volume29
Issue number6
StatePublished - Jun 1 2015

Fingerprint

zoledronic acid
Castration
Prostatic Neoplasms
Costs and Cost Analysis
Radium
Morbidity
Safety
Mortality
Therapeutics
Denosumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. / Graff, Julie; Beer, Tomasz (Tom).

In: Oncology (Williston Park, N.Y.), Vol. 29, No. 6, 01.06.2015, p. 416-423.

Research output: Contribution to journalReview article

@article{dd72ce06230f40469f4dbdf01db92e2c,
title = "Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer",
abstract = "Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223. We include data on and a discussion of duration of treatment with zoledronic acid and denosumab, the only two of these agents that do not have a clinically proven anticancer effect. Finally, we review the available data regarding the cost of denosumab compared with that of zoledronic acid.",
author = "Julie Graff and Beer, {Tomasz (Tom)}",
year = "2015",
month = "6",
day = "1",
language = "English (US)",
volume = "29",
pages = "416--423",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "6",

}

TY - JOUR

T1 - Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

AU - Graff, Julie

AU - Beer, Tomasz (Tom)

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223. We include data on and a discussion of duration of treatment with zoledronic acid and denosumab, the only two of these agents that do not have a clinically proven anticancer effect. Finally, we review the available data regarding the cost of denosumab compared with that of zoledronic acid.

AB - Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223. We include data on and a discussion of duration of treatment with zoledronic acid and denosumab, the only two of these agents that do not have a clinically proven anticancer effect. Finally, we review the available data regarding the cost of denosumab compared with that of zoledronic acid.

UR - http://www.scopus.com/inward/record.url?scp=85047595803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047595803&partnerID=8YFLogxK

M3 - Review article

C2 - 26091674

AN - SCOPUS:84934905491

VL - 29

SP - 416

EP - 423

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 6

ER -